Open AccessUS food and drug administration Indian site inspections: An experience
Author(s) -
Pooja Mahajan,
Natasha D'Souza,
Arun Bhatt,
Vipul Halbe,
Richa Sharma,
Shweta Narayanswamy,
Murtuza Bughediwala
Publication year - 2012
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/2229-3485.96453
Subject(s) - documentation , food and drug administration , audit , inspector general , medicine , protocol (science) , accountability , clinical trial , business , informed consent , medical emergency , family medicine , medical education , alternative medicine , political science , accounting , law , pathology , computer science , programming language
Since 2005, USFDA has begun inspections of Indian clinical trial investigator sites. This paper reports experience of an FDA inspection performed at two Indian centers. The inspection started with an in-depth discussion with the investigator and his team about the conduct of the clinical trial at the site and was followed by a tour of the important locations - registration, outpatient department, specialty clinic, medical record section, and special procedure department. The inspector reviewed the critical processes - protocol compliance, ethics committee approval, informed consent process, case record form and source documents completion, investigational product accountability, serious adverse events documentation and reporting. The inspector reviewed all documents from the investigator site file and conducted audit of all subjects enrolled at both the sites. As the Indian sites are not exposed to regulatory inspections, it is vital for the sponsor to conduct preinspection audit, provide training and support to face the FDA inspection.